Showing 211-220 of 665 results for "".
Pipeline and Potential Roles for GLP-1RAs in Dermatology
https://practicaldermatology.com/issues/novemberdecember-2025/pipeline-and-potential-roles-for-glp-1ras-in-dermatology/48898/Having reviewed the mechanism of action and current roles in medicine for glucagon-like peptide 1 receptor agonists (GLP-1RAs), we now can discuss therapies in this class currently under investigation for management of dermatologic disease.Case Report: Pityriasis Versicolor: Using the Wood's Lamp in Diagnosis; Residents of Distinction Honored
https://practicaldermatology.com/youngmd-connect/resident-resource-center/case-report-pityriasis-versicolor-using-the-woods-lamp-in-diagnosis-residents-of-distinction-honored/21011/Vitamin D and Psoriasis
https://practicaldermatology.com/topics/practice-management/vitamin-d-and-psoriasis/21470/New findings suggest a relationship between psoriasis and vitamin D deficiency, but larger details are still unknown.Dupilumab For the Management of Pembrolizumab-induced Rash: A Case Report
https://practicaldermatology.com/youngmd-connect/resident-resource-center/dupilumab-for-the-management-of-pembrolizumab-induced-rash-a-case-report/23841/"Psleep": Psoriasis and Sleep
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/psleep-psoriasis-and-sleep/29075/The “invisible” impacts of psoriasis are those not directly seen on examination. These include itch, pain, fatigue and sleep dysfunction, which may be improved by our systemic therapies. However, there is a gap between the patients’ reporting of these experienced invisible impacts and their physiciaA Long View: Conceptions of Atopic Dermatitis Through the Ages
https://practicaldermatology.com/topics/general-topics/a-long-view-conceptions-of-atopic-dermatitis-through-the-ages/21261/Is Irritable Bowel Linked to Irritable Skin?
https://practicaldermatology.com/columns/clinical-focus-1/is-irritable-bowel-linked-to-irritable-skin/23324/Exploring irritable bowel syndrome’s link to dermatologic conditions.Biosimilar Medicines in Dermatology: Key Aspects
https://practicaldermatology.com/topics/psoriasis/biosimilar-medicines-in-dermatology-key-aspects/22929/After the recent enactment of a specific approval pathway for biosimilars and publication of the first draft guidelines on biosimilar product development by the FDA, biosimilars are expected to be available in the US soon.The Excoriated and Bleeding Edge: Updates in Eczema for the Clinician
https://practicaldermatology.com/topics/general-topics/the-excoriated-and-bleeding-edge-updates-in-eczema-for-the-clinician/21469/Atopic dermatitis continues to present treatment challenges, but a steady juggling of four main components—moisturization, antibiotics, anti-inflammatory, and antipruritics— help to maximize control of the disease.Journal Club: Biologics for Young Children
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-biologics-for-young-children/32400/Practical Dermatology Editorial Board member Lawrence Eichenfield, MD, FAAD, Dawn Eichenfield, MD, PhD, discuss the article "Biologic therapies in infants and children younger than 6 years of age with atopic dermatitis: suitability and practical considerations," from Expert Opinion on Drug Safety. R